Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing

Cellectar Biosciences, Inc.

2026-Q1 EPS reported -$1.33

Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.
Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.
Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.
Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.
Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-060693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.